journal article·2024-05Open access

Molecular Engineering of Electrosprayed Hydrogel Microspheres to Achieve Synergistic Anti‐Tumor Chemo‐Immunotherapy with ACEA Cargo

Youming Deng, Jiayang Li, Ran Tao, Ke Zhang, Rong Yang, Zhan Qu, Yu Zhang, Jinjian Huang

Advanced Science· Volume 11· Issue 17

Abstract

Abstract Molecular engineering of drug delivering platforms to provide collaborative biological effects with loaded drugs is of great medical significance. Herein, cannabinoid receptor 1 (CB1)‐ and reactive oxygen species (ROS)‐targeting electrosprayed microspheres (MSs) are fabricated by loading with the CB1 agonist arachidonoyl 2′‐chloroethylamide (ACEA) and producing ROS in a photoresponsive manner. The synergistic anti‐tumor effects of ACEA and ROS released from the MSs are assessed. ACEA inhibits epidermal growth factor receptor signaling and altered tumor microenvironment (TME) by activating CB1 to induce tumor cell death. The MSs are composed of glycidyl methacrylate‐conjugated xanthan gum (XGMA) and Fe3+, which form dual molecular networks based on a Fe3+‐(COO−)3 network and a C═C addition reaction network. Interestingly, the Fe3+‐(COO−)3 network can be disassembled instantly under the conditions of lactate sodium and ultraviolet exposure, and the disassembly is accompanied by massive ROS production, which directly injures tumor cells. Meanwhile, the transition of dual networks to a single network boosts the ACEA release. Together, the activities of the ACEA and MSs promote immunogenic tumor cell death and create a tumor‐suppressive TME by increasing M1‐like tumor‐associated macrophages and CD8+ T cells. In summation, this study demonstrates strong prospects of improving anti‐tumor effects of drug delivering platforms through molecular design.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of General Surgery Xiangya Hospital International Joint Research Center of Minimally Invasive Endoscopic Technology Equipment and Standards Central South University Changsha 410008 China

Research Institute of General Surgery Jinling Hospital School of Medicine Nanjing University Nanjing 210002 China

Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) School of Basic Medical Sciences Fudan University Shanghai 200032 China

Funding

Natural Science Foundation of Jiangsu Province · China Postdoctoral Science Foundation · Natural Science Foundation of Hunan Province · National Natural Science Foundation of China

References (60)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1158/2159-8290.CD-14-086310.1158/2159-8290.CD-14-0863 ↗
3. 10.1146/annurev-cancerbio-030518-05555210.1146/annurev-cancerbio-030518-055552 ↗
4. 10.1126/science.aar406010.1126/science.aar4060 ↗
5. 10.1038/s41573-018-0006-z10.1038/s41573-018-0006-z ↗
6. 10.3322/caac.2159610.3322/caac.21596 ↗
7. 10.1038/s41577-021-00541-y10.1038/s41577-021-00541-y ↗
8. 10.7554/eLife.5518510.7554/eLife.55185 ↗
9. 10.1016/j.bpsc.2020.07.01610.1016/j.bpsc.2020.07.016 ↗
10. 10.3390/ijms2306304910.3390/ijms23063049 ↗
11. 10.3390/ijms2007167310.3390/ijms20071673 ↗
12. 10.3390/ijms2406552410.3390/ijms24065524 ↗
13. 10.1084/jem.2017144010.1084/jem.20171440 ↗
14. 10.1016/j.celrep.2021.10984410.1016/j.celrep.2021.109844 ↗
15. 10.3389/fimmu.2020.0173110.3389/fimmu.2020.01731 ↗
16. 10.7150/thno.5092810.7150/thno.50928 ↗
17. 10.1016/j.bioactmat.2020.12.01010.1016/j.bioactmat.2020.12.010 ↗
18. 10.1038/s41420-022-01064-810.1038/s41420-022-01064-8 ↗
19. 10.3389/fimmu.2019.0165410.3389/fimmu.2019.01654 ↗
20. 10.1038/s41571-020-0413-z10.1038/s41571-020-0413-z ↗
21. 10.1016/j.bioactmat.2021.10.03010.1016/j.bioactmat.2021.10.030 ↗
22. 10.1093/rb/rbaa00910.1093/rb/rbaa009 ↗
23. 10.1016/j.colsurfb.2019.11064510.1016/j.colsurfb.2019.110645 ↗
24. 10.1002/smll.20220031410.1002/smll.202200314 ↗
25. 10.1016/j.bioadv.2023.21339810.1016/j.bioadv.2023.213398 ↗
26. 10.1016/j.jconrel.2021.08.04910.1016/j.jconrel.2021.08.049 ↗
27. 10.1016/j.bioactmat.2020.11.02910.1016/j.bioactmat.2020.11.029 ↗
28. 10.1021/acs.biomac.8b0073410.1021/acs.biomac.8b00734 ↗
29. 10.1002/adma.20230054810.1002/adma.202300548 ↗
30. 10.1016/j.ijpharm.2017.12.03610.1016/j.ijpharm.2017.12.036 ↗
31. 10.7150/thno.5002810.7150/thno.50028 ↗
32. 10.1016/j.jconrel.2022.09.02010.1016/j.jconrel.2022.09.020 ↗
33. 10.7150/thno.8785410.7150/thno.87854 ↗
34. 10.3390/ijms2301053910.3390/ijms23010539 ↗
35. 10.1088/1758-5090/ab8bc310.1088/1758-5090/ab8bc3 ↗
36. 10.1002/sia.198410.1002/sia.1984 ↗
37. 10.1016/j.apsusc.2007.09.06310.1016/j.apsusc.2007.09.063 ↗
38. 10.1016/j.bioactmat.2022.06.00510.1016/j.bioactmat.2022.06.005 ↗
39. 10.1016/j.bioactmat.2023.01.01110.1016/j.bioactmat.2023.01.011 ↗
40. 10.3390/gels905036710.3390/gels9050367 ↗
41. 10.1016/j.carbpol.2023.12064410.1016/j.carbpol.2023.120644 ↗
42. 10.1038/s41467-023-36630-w10.1038/s41467-023-36630-w ↗
43. 10.1038/s41467-023-41724-610.1038/s41467-023-41724-6 ↗
44. 10.1038/s41577-023-00894-610.1038/s41577-023-00894-6 ↗
45. 10.3748/wjg.v25.i31.438310.3748/wjg.v25.i31.4383 ↗
46. 10.1126/sciimmunol.aba842610.1126/sciimmunol.aba8426 ↗
47. 10.3389/fimmu.2019.0204010.3389/fimmu.2019.02040 ↗
48. 10.1038/s41467-019-11788-410.1038/s41467-019-11788-4 ↗
49. 10.1038/s41467-020-17914-x10.1038/s41467-020-17914-x ↗
50. 10.1016/j.isci.2022.10375810.1016/j.isci.2022.103758 ↗
51. 10.1002/adma.20210349710.1002/adma.202103497 ↗
52. 10.1016/j.mtbio.2023.10055510.1016/j.mtbio.2023.100555 ↗
53. 10.1016/j.bioactmat.2022.03.00810.1016/j.bioactmat.2022.03.008 ↗
54. 10.1038/s41590-022-01379-910.1038/s41590-022-01379-9 ↗
55. 10.1016/j.cell.2020.09.04810.1016/j.cell.2020.09.048 ↗
56. 10.1002/1521-4141(200203)32:3<731::AID-IMMU731>3.0.CO;2-H10.1002/1521-4141(200203)32:3<731::AID-IMMU731>3.0.CO;2-H ↗
57. 10.1371/journal.pone.001114410.1371/journal.pone.0011144 ↗
58. 10.1016/j.tcb.2020.06.00310.1016/j.tcb.2020.06.003 ↗
59. 10.1039/D0NR02552F10.1039/D0NR02552F ↗
60. 10.1021/acs.accounts.2c0069910.1021/acs.accounts.2c00699 ↗